Friday, May 3, 2013
Incyte Corp., of Wilmington, Del., posted net product revenues from sales of myelofibrosis drug Jakafi (ruxolitinib) totaling $48.3 million for the first quarter, with product royalties from sales of the drug, marketed as Jakavi outside the U.S. by partner Novartis AG, of Basel, Switzerland, totaling $5.9 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.